Clinical Pipeline

About
Our pipeline
With an initial focus on insomnia in PTSD (RE03), treatment-resistant generalized anxiety disorder (RE02), and cocaine and stimulant use disorder (RE01), we are building a platform of drug candidates with transdiagnostic potential for multiple sleep, anxiety and substance use disorders.
Development pipeline
Development pipeline
About
About
α2 nor-adrenergic receptor agonist
RE03, Reconnect’s proprietary regenerative sleep drug candidate, is a repurposed globally approved medicine being evaluated for insomnia in PTSD, a condition which impacts over 80% of PTSD patients, and stress-induced primary Insomnia which impacts over 50% of insomniacs.

Employing a novel mechanism of action, RE03 is the only insomnia drug candidate in clinical development to target noradrenergic signaling, a neurological process which causes elevated arousal and wakefulness under stress.

Based on healthy human study results, RE03 has demonstrated an increase and consolidation in NREM and REM sleep, leading to an overall improvement in sleep architecture, restorative sleep and daytime functioning, the hallmarks of natural regenerative sleep. Study results indicate these benefits are achieved without the hangover effects or orthostatic dysregulation typical of most sleep medications. With its low side-effect, tolerance and dependency risk profile, and its ability to improve comorbid psychiatric symptoms, RE03 offers the potential of a disease modifying, first-in-class treatment for insomnia in PTSD, and stress-induced primary insomnia.

Development status – next steps: Phase 2a clinical trial in insomnia in PTSD.

Neuroplasticity promoting 5-HT1A agonist
RE02, Reconnect’s patented, precision-formulated, 5-HT1A agonist is a rapid-acting, non-addictive anxiolytic being evaluated for use in treatment-resistant generalized anxiety disorder.

RE02 has been engineered to entirely remove the psychedelic effects of the compound and to maximize the therapeutic effects of 5-HT1A agonists within an accessible, well-tolerated, and scalable sublingual administration.

Based on healthy human study results, RE02 has demonstrated highly improved pharmacokinetic profile and highly differentiated pharmacodynamics as compared to other compounds in this the same class of molecules.

Development status –  next steps: Phase 2a clinical trial in treatment-resistant generalized anxiety disorder (GAD).

5-HT2A agonist + dopamine modulator, fixed-combination
RE01, Reconnect’s patented, fixed-combination drug candidate is a precision-formulated psychoplastogen with a rapid-onset, short duration, and novel psychoactive effect. Employing an innovative serotonergic and dopamine modulating mechanism of action, RE01 is being investigated for cocaine and stimulant use disorder.

Based on healthy human study results, RE01 has demonstrated superior bioavailability, and an improved pharmacokinetic and pharmacodynamic profile in comparison to other 5-HT2A agonists in the same class of compounds.

Administered via Reconnect’s exclusively licensed sublingual technology in combination with a precision dosing regime, RE01 provides a highly controllable and precise therapeutic dosing range targeting select neurobiological and psychological mechanisms of action. Formulated to minimize unpredictable and adverse changes to perceptual and cognitive functions, RE01 offers the potential to provide immediate symptom alleviation and long-term disease modification with few side effects.

Development status – next steps: Phase 2a clinical trial in cocaine use disorder.

* Forward-looking statements are subject to risks and assumptions. Subject to receipt of all necessary regulatory approvals from all applicable governmental authorities, including, as applicable, the academic and scientific organizations with which Reconnect Labs is working.
About
About
α2 nor-adrenergic receptor agonist
RE03, Reconnect’s proprietary regenerative sleep drug candidate, is a repurposed globally approved medicine being evaluated for insomnia in PTSD, a condition which impacts over 80% of PTSD patients, and stress-induce primary Insomnia which impacts over 50% of insomniacs.

Employing a novel mechanism of action, RE03 is the only insomnia drug candidate in clinical development to target noradrenergic signaling, a neurological process which causes elevated arousal and wakefulness under stress.

Based on healthy human study results, RE03 has demonstrated an increase and consolidation in NREM and REM sleep, leading to an overall improvement in sleep architecture, restorative sleep and daytime functioning, the hallmarks of natural regenerative sleep. Study results indicate these benefits are achieved without the hangover effects or orthostatic dysregulation typical of most sleep medications. With its low side-effect, tolerance and dependency risk profile, and its ability to improve comorbid psychiatric symptoms, RE03 offers the potential of a disease modifying, first-in-class treatment for insomnia in PTSD, and stress-induced primary insomnia.

Development status: Phase 2a clinical trial in insomnia in PTSD.

Neuroplasticity promoting 5-HT1A agonist
RE02, Reconnect’s patented, precision-formulated, 5-HT1A agonist is a rapid-acting, non-addictive anxiolytic being evaluated for use in treatment resistant generalized anxiety disorder.

RE02 has been engineered to entirely remove the psychedelic effects of the compound and to maximize the therapeutic effects of 5-HT1A agonists within an accessible, well-tolerated, and scalable sublingual administration.

Based on healthy human study results, RE02 has demonstrated highly improved pharmacokinetic profile and highly-differentiated pharmacodynamics as compared to other compounds in this the same class of molecules.

Development status: Phase 2a clinical trial in treatment resistant generalized anxiety disorder (GAD).

5-HT2A agonist + dopamine modulator, fixed-combination
RE01, Reconnect’s patented, fixed-combination drug candidate is a precision-formulated psychoplastogen with a rapid-onset, short duration, and novel psychoactive effect. Employing an innovative serotonergic and dopamine modulating mechanism of action, RE01 is being investigated for cocaine and stimulant use disorder.

Based on healthy human study results, RE01 has demonstrated superior bioavailability, and an improved pharmacokinetic and pharmacodynamic profile in comparison to other 5-HT2A agonists in the same class of compounds.

Administered via Reconnect’s exclusively licensed sublingual technology in combination with a precision dosing regime, RE01 provides a highly controllable and precise therapeutic dosing range targeting select neurobiological and psychological mechanisms of action. Formulated to minimize unpredictable and adverse changes to perceptual and cognitive functions, RE01 offers the potential to provide immediate symptom alleviation and long-term disease modification with few side effects.

Development status: Phase 2a clinical trial in cocaine use disorder.

*Forward-looking statements are subject to risks and assumptions. Subject to receipt of all necessary regulatory approvals from all applicable governmental authorities, including, as applicable, the academic and scientific organizations with which Reconnect Labs is working.

About

We’d like to
hear from you.

info@reconnect-labs.com

    About Us

    Investors

    Our Work

    ©2024 Reconnect Labs AG. All rights reserved.

    Contact-Block

    We’d like to hear from you.

    info@reconnect-labs.com

      About Us

      Investors

      Our Work

      ©2024 Reconnect Labs AG. All rights reserved.

      Contact-Block